HepaRegeniX Secures €15 Million Series C Funding to Propel Clinical Development of HRX-215 for Liver Regeneration
HepaRegeniX GmbH, a pioneering clinical-stage biotechnology firm specializing in regenerative therapies for liver diseases, has announced the successful closure of a Series C funding round totaling €15 million. Led by Vesalius Biocapital IV and supported by existing investors including Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds (HTGF), this investment will accelerate the…